State Street SPDR S&P Biotech ETF
123 hedge funds and large institutions have $1.6B invested in State Street SPDR S&P Biotech ETF in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 56 reducing their positions, and 29 closing their positions.
6% less funds holding
Funds holding: 131 → 123 (-8)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
40% less capital inflows, than outflows
Capital inflows: $211M | Capital outflows: $349M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
54% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 56
78% less call options, than puts
Call options by funds: $10.7M | Put options by funds: $48.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$96.6M |
| 2 |
UBS
Zurich,
Switzerland
|
+$38.2M |
| 3 |
Sandler Capital Management
New York
|
+$17.9M |
| 4 |
Barclays
London,
United Kingdom
|
+$13.7M |
| 5 |
Morgan Stanley
New York
|
+$9.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$97.2M |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
-$59.6M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$37.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22.9M |
| 5 |
Psagot Value Holdings
Tel Aviv,
Israel
|
-$18.8M |
XBI Hedge Fund Activity: Q2 2014 in Review
123 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2014, worth a combined $1.6B — down 1.4% from $1.62B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of XBI and 22 opened new positions — a net loss of 7 holders — while 56 trimmed existing stakes and 26 added.
The largest buyer was Goldman Sachs, adding an estimated $96.6M. The largest seller was Mirae Asset Global Investments, cutting an estimated $97.2M.
- 123 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2014, down from 131 in Q1 2014.
- Funds reported $1.6B of State Street SPDR S&P Biotech ETF stock for Q2 2014, down 1.4% quarter-over-quarter.
- 22 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2014 and 29 closed out, a net change of -7 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2014 was Goldman Sachs, an estimated $96.6M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2014 was Mirae Asset Global Investments, an estimated $97.2M sold.
Based on aggregated 13F filings for Q2 2014.